Zhenghai Bio-Tech released its 2026 interim report. First-half net profit attributable to the parent was 33.31 million yuan, down 27.85% year on year. Operating revenue was 160 million yuan, down 14.94% year on year. Net profit attributable to the parent after deducting non-recurring items was 27.16 million yuan, down 31.74% year on year. Net operating cash flow was 28.29 million yuan, down 40.65% year on year. Second-quarter net profit attributable to the parent was 18.56 million yuan, down 6.6% year on year. The company said its main business has not undergone major changes and remains focused on regenerative medicine, mainly providing Class III medical device products.
Yantai Zhenghai Bio-Tech Co LtdFirst-half net profit fell 27.85% and revenue dropped 14.94%.
